HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial

BACKGROUND: Irinotecan is used as second-line treatment in advanced gastric or gastroesophageal junction (G/GEJ) cancer. The role of anti-programmed death-1 (PD-1) antibody plus irinotecan, in this setting and population is unclear. METHODS: This multicenter, open-label, single-arm, phase II trial w...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yan, Li, Ning, Li, Qun, Liang, Xinjun, Zhang, Shu, Fan, Qingxia, Yin, Xianli, Zhuang, Zhixiang, Liu, Yunpeng, Zhang, Jingdong, Kou, Xiaoge, Zhong, Haijun, Wang, Xiaofei, Dou, Yiwei, Huang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566427/
https://www.ncbi.nlm.nih.gov/pubmed/33060149
http://dx.doi.org/10.1136/jitc-2020-001279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566427/
https://www.ncbi.nlm.nih.gov/pubmed/33060149
http://dx.doi.org/10.1136/jitc-2020-001279

Ejemplares similares